Issues And Trends In Healthcare Delivery System
Pre-Procedural Guidelines for Assessing Blood Pressure
Cardiovascular Drugs: Classification based on Therapeutic Indications
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: May 15, 2025

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Marci Farquhar-Snow1, Amy E Simone, Sheel V Singh
1Marci Farquhar-Snow is a retired assistant professor, formerly practicing in the Department of Cardiovascular Medicine at Mayo Clinic College of Medicine and Science in Scottsdale, Ariz. Amy E. Simone is a consultant at Edwards Lifesciences in Burlingame, Calif. Sheel V. Singh is a second-year student in the PhD program in Health and Rehabilitation Sciences at Massachusetts General Hospital Institute of Health Professions in Boston, Mass. Reamer L. Bushardt is provost and vice president for academic affairs and a professor at Massachusetts General Hospital Institute of Health Professions, as well as a research associate in the Department of Physical Medicine and Rehabilitation at Harvard Medical School in Boston, Mass. Marci Farquhar-Snow serves on the Cardiovascular Team Editorial Board at the Journal of the American College of Cardiology . Amy E. Simone is chair-elect, CV Team Section Leadership Council, American College of Cardiology, and founder of JC Medical. Reamer L. Bushardt is editor-in-chief emeritus of JAAPA . The authors have disclosed no other potential conflicts of interest, financial or otherwise.
Artificial intelligence (AI) is transforming cardiovascular care by introducing new models and applications. Clinicians play a vital role in the ethical development and adoption of these advanced AI technologies.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: